Comparative Pharmacology
Head-to-head clinical analysis: BENZNIDAZOLE versus IMPAVIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZNIDAZOLE versus IMPAVIDO.
BENZNIDAZOLE vs IMPAVIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benznidazole is a nitroimidazole derivative that exerts trypanocidal activity against Trypanosoma cruzi. Its mechanism involves the reduction of the nitro group by a nitroreductase enzyme in the parasite, leading to the generation of toxic metabolites that damage parasite DNA and other cellular components.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
5-7 mg/kg/day orally divided into two daily doses for 60 days. Maximum daily dose: 300 mg.
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
None Documented
None Documented
Clinical Note
moderateBenznidazole + Leflunomide
"The risk or severity of adverse effects can be increased when Benznidazole is combined with Leflunomide."
Clinical Note
moderateBenznidazole + Fingolimod
"Benznidazole may increase the immunosuppressive activities of Fingolimod."
Clinical Note
moderateBenznidazole + Tofacitinib
"Benznidazole may increase the immunosuppressive activities of Tofacitinib."
Clinical Note
moderatePimecrolimus + Benznidazole
Terminal elimination half-life is approximately 12 hours; may be prolonged in hepatic impairment.
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
Primarily renal excretion of metabolites; <5% unchanged drug. Approximately 20% in feces.
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Category C
Category C
Antiprotozoal
Antiprotozoal
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Benznidazole."